本文選題：前列腺癌　切入點(diǎn)：脂代謝　出處：《中國(guó)老年學(xué)雜志》2017年22期

【摘要】：目的探討脂代謝調(diào)節(jié)對(duì)老年前列腺癌患者治療效果的影響。方法選取老年前列腺癌患者126例進(jìn)行回顧性分析,依據(jù)治療方法的不同分為治療組及對(duì)照組各63例,對(duì)照組接受氟他胺聯(lián)合戈舍瑞林進(jìn)行治療,治療組在對(duì)照組治療方案的基礎(chǔ)上加用阿托伐他汀進(jìn)行治療。比較兩組治療前及治療過程中前列腺特異抗原(PSA)水平、血脂水平、治療療效及不良反應(yīng)情況。結(jié)果治療前兩組患者PSA、總膽固醇(TC)及甘油三酯(TG)水平比較差異無統(tǒng)計(jì)學(xué)意義(P0.05);治療6個(gè)月及12個(gè)月后治療組PSA水平顯著低于對(duì)照組(P0.05);治療12個(gè)月后治療組TC及TG水平明顯低于對(duì)照組(P0.05);治療組治療療效顯著優(yōu)于對(duì)照組(P0.05);治療過程中兩組不良反應(yīng)情況比較差異無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論老年前列腺癌患者進(jìn)行常規(guī)治療基礎(chǔ)上加用阿托伐他汀進(jìn)行調(diào)脂治療可顯著降低患者的PSA、TC及TG水平,提高腫瘤治療效果,且無其他明顯不良反應(yīng)。
[Abstract]:Objective to investigate the effect of lipid metabolism regulation on the treatment of prostate cancer in elderly patients.Methods 126 elderly patients with prostate cancer were retrospectively analyzed and divided into treatment group (n = 63) and control group (n = 63). The control group was treated with flutamide combined with goserelin.The treatment group was treated with Atto vastatin on the basis of the control group.The levels of prostate specific antigen (PSA), blood lipid, therapeutic efficacy and adverse reactions were compared between the two groups before and during treatment.Results before treatment, there was no significant difference between the two groups in the levels of PSA, total cholesterol and triglyceride, the levels of PSA in the treatment group were significantly lower than those in the control group after 6 and 12 months of treatment, and the levels of TC and TG in the treatment group were significantly lower than those in the control group after 12 months of treatment, and the levels of TC and TG in the treatment group were significantly lower than those in the control group after 12 months of treatment.The level of the treatment group was significantly lower than that of the control group (P 0.05), the therapeutic effect of the treatment group was significantly better than that of the control group (P 0.05), and there was no significant difference in the adverse reactions between the two groups during the course of treatment.Conclusion on the basis of routine therapy, the combination of Atto vastatin and lipid-regulating therapy can significantly reduce the levels of PSATC and TG, and improve the therapeutic effect of prostate cancer, and there are no other adverse reactions.
【作者單位】： 長(zhǎng)春醫(yī)學(xué)高等�？茖W(xué)校;吉林大學(xué)第一醫(yī)院內(nèi)分泌代謝科;
【分類號(hào)】：R737.25

【相似文獻(xiàn)】

相關(guān)期刊論文 前4條

1 宋豎旗;張亞強(qiáng);盧建新;;“骨頭不痛” 前列腺癌 悄悄在轉(zhuǎn)移[J];家庭中醫(yī)藥;2014年05期

2 林志弟;莫林鍵;張成東;宣強(qiáng);張悅寧;莫曾南;滕若冰;楊小麗;;高表達(dá)重組人組織激肽釋放酶7基因的前列腺癌單克隆細(xì)胞株的構(gòu)建[J];山東醫(yī)藥;2014年10期

3 袁立英;班遵浦;江朝友;;原發(fā)性腎病綜合征激素治療中脂代謝變化的臨床觀察[J];遵義醫(yī)學(xué)院學(xué)報(bào);2005年05期

4 方衛(wèi)東;;低分子肝素對(duì)血液透析患者脂代謝的影響[J];實(shí)用臨床醫(yī)學(xué);2005年12期

相關(guān)博士學(xué)位論文 前9條

1 阿卜杜（ABDULALAM ABDULRAB M.F）;神經(jīng)降壓素在去勢(shì)抵抗性前列腺癌神經(jīng)內(nèi)分泌分型中的應(yīng)用[D];天津醫(yī)科大學(xué);2017年

2 張慧明;ALKBH與前列腺癌關(guān)系的初步研究[D];鄭州大學(xué);2017年

3 王亮;HSPC111基因表達(dá)與前列腺癌放射敏感性關(guān)系的研究[D];天津醫(yī)科大學(xué);2017年

4 姜行康;microRNA-503通過ZNF217抑制前列腺癌進(jìn)展的機(jī)制研究[D];天津醫(yī)科大學(xué);2017年

5 田煥書;miR-218調(diào)控前列腺癌腫瘤干細(xì)胞干性及其分子機(jī)制研究[D];暨南大學(xué);2017年

6 武丹;以FKBP51為靶點(diǎn)的小分子抑制前列腺癌AR信號(hào)通路[D];蘭州大學(xué);2017年

7 范校周;基于納米泡的前列腺癌超聲靶向診斷及治療的實(shí)驗(yàn)研究[D];第三軍醫(yī)大學(xué);2017年

8 李凱;NOP16低表達(dá)增強(qiáng)前列腺癌化療敏感性的初步研究[D];天津醫(yī)科大學(xué);2017年

9 閆澤晨;PHD3對(duì)Desmin的調(diào)控在前列腺癌骨轉(zhuǎn)移中的作用及分子機(jī)制[D];鄭州大學(xué);2017年

相關(guān)碩士學(xué)位論文 前2條

1 岳園園;靶向前列腺癌的兩種探針的研究[D];鄭州大學(xué);2017年

2 應(yīng)暢;Ⅰ靶向抑制Notch1信號(hào)通路對(duì)人喉癌干細(xì)胞化療增敏的研究 ⅡGP73調(diào)控的溶瘤腺病毒GD55對(duì)前列腺癌干細(xì)胞殺傷效果[D];浙江理工大學(xué);2017年

，

本文編號(hào)：1715144